Clinical Trial Update: CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This document reports a Phase 1 clinical trial update on the combination of telaglenastat (CB-839) with carfilzomib and dexamethasone for patients with recurren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Telaglenastat (telaglenastat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING